Financhill
Buy
58

DVAX Quote, Financials, Valuation and Earnings

Last price:
$10.89
Seasonality move :
10.12%
Day range:
$10.87 - $11.03
52-week range:
$9.20 - $14.63
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
4.55x
P/B ratio:
2.39x
Volume:
1.1M
Avg. volume:
1.7M
1-year change:
-15.12%
Market cap:
$1.3B
Revenue:
$277.2M
EPS (TTM):
-$0.38

Analysts' Opinion

  • Consensus Rating
    Dynavax Technologies Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $19.25, Dynavax Technologies Corp. has an estimated upside of 76.77% from its current price of $10.89.
  • Price Target Downside
    According to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $10.89.

Fair Value

  • According to the consensus of 4 analysts, Dynavax Technologies Corp. has 76.77% upside to fair value with a price target of $19.25 per share.

DVAX vs. S&P 500

  • Over the past 5 trading days, Dynavax Technologies Corp. has underperformed the S&P 500 by -4.52% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Dynavax Technologies Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Dynavax Technologies Corp. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Dynavax Technologies Corp. reported revenues of $94.9M.

Earnings Growth

  • Dynavax Technologies Corp. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dynavax Technologies Corp. reported earnings per share of $0.21.
Enterprise value:
920.2M
EV / Invested capital:
1.12x
Price / LTM sales:
4.55x
EV / EBIT:
88.16x
EV / Revenue:
2.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.43x
Price / Operating cash flow:
18.68x
Enterprise value / EBITDA:
49.26x
Gross Profit (TTM):
$274.9M
Return On Assets:
-4.47%
Net Income Margin (TTM):
-13.13%
Return On Equity:
-7.65%
Return On Invested Capital:
-5.15%
Operating Margin:
22.42%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $361.2M $260.8M $330.5M $80.6M $94.9M
Gross Profit $242.2M $216.1M $274.9M $67.5M $80.5M
Operating Income $36.7M -$7.4M $10.4M $10.1M $21.3M
EBITDA $43.5M $496K $18.7M $12.1M $23.4M
Diluted EPS $0.38 $0.13 -$0.38 $0.11 $0.21
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $852.7M $932.9M $835.7M $926.2M $814.3M
Total Assets $919.7M $999.3M $972.9M $1.1B $946.5M
Current Liabilities $528.9M $244.1M $54.3M $70M $106.8M
Total Liabilities $852.1M $498.8M $368M $380.6M $412.4M
Total Equity $67.6M $500.6M $604.9M $681.4M $534.1M
Total Debt $255.2M $254.4M $253.1M $250.2M $285M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $121.7M $27.3M $90.6M $19.5M $33.8M
Cash From Investing -$166.7M -$61.6M $152.4M -$15.5M $27.3M
Cash From Financing -$237K -$1.4M -$202.7M $2.5M -$61K
Free Cash Flow $117.8M $22.7M $80.5M $18.1M $32.6M
DVAX
Sector
Market Cap
$1.3B
$28.5M
Price % of 52-Week High
74.44%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
11.99%
-1.33%
1-Year Price Total Return
-15.12%
-20.32%
Beta (5-Year)
0.886
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $11.09
200-day SMA
Sell
Level $10.94
Bollinger Bands (100)
Buy
Level 9.92 - 11.04
Chaikin Money Flow
Buy
Level 44.7M
20-day SMA
Sell
Level $11.11
Relative Strength Index (RSI14)
Buy
Level 50.04
ADX Line
Sell
Level 21.2
Williams %R
Neutral
Level -72.6287
50-day SMA
Buy
Level $10.53
MACD (12, 26)
Buy
Level 0.12
25-day Aroon Oscillator
Buy
Level 56
On Balance Volume
Neutral
Level 264.1M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.3904)
Buy
CA Score (Annual)
Level (0.1513)
Buy
Beneish M-Score (Annual)
Level (-2.973)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.9664)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Stock Forecast FAQ

In the current month, DVAX has received 3 Buy ratings 0 Hold ratings, and 1 Sell ratings. The DVAX average analyst price target in the past 3 months is $19.25.

  • Where Will Dynavax Technologies Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Dynavax Technologies Corp. share price will rise to $19.25 per share over the next 12 months.

  • What Do Analysts Say About Dynavax Technologies Corp.?

    Analysts are divided on their view about Dynavax Technologies Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dynavax Technologies Corp. is a Sell and believe this share price will drop from its current level to $11.00.

  • What Is Dynavax Technologies Corp.'s Price Target?

    The price target for Dynavax Technologies Corp. over the next 1-year time period is forecast to be $19.25 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is DVAX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Dynavax Technologies Corp. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of DVAX?

    You can purchase shares of Dynavax Technologies Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dynavax Technologies Corp. shares.

  • What Is The Dynavax Technologies Corp. Share Price Today?

    Dynavax Technologies Corp. was last trading at $10.89 per share. This represents the most recent stock quote for Dynavax Technologies Corp.. Yesterday, Dynavax Technologies Corp. closed at $10.89 per share.

  • How To Buy Dynavax Technologies Corp. Stock Online?

    In order to purchase Dynavax Technologies Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock